RIVASTIGMINE TARTRATE (rivastigmine tartrate) by Molecular Devices is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. Approved for mild-to-moderate dementia of the alzheimer's type (ad), mild-to-moderate dementia associated with parkinson’s disease (pd). First approved in 2017.
Drug data last refreshed 1w ago
unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. Therefore, the effect of rivastigmine may lessen as the disease process…
Worked on RIVASTIGMINE TARTRATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.